WO2006097970A1 - Use of inhibitors of steroid (testosterone) activity (i. a. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse - Google Patents
Use of inhibitors of steroid (testosterone) activity (i. a. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse Download PDFInfo
- Publication number
- WO2006097970A1 WO2006097970A1 PCT/IT2006/000168 IT2006000168W WO2006097970A1 WO 2006097970 A1 WO2006097970 A1 WO 2006097970A1 IT 2006000168 W IT2006000168 W IT 2006000168W WO 2006097970 A1 WO2006097970 A1 WO 2006097970A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- use according
- testosterone
- substances
- steroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Definitions
- the present invention concerns the use of inhibitors of the 5 steroid activity for the treatment of substance related disorders.
- the present Invention concerns the use of one or more steroid activity inhibitors, namely androgens, such as testosterone, for the treatment of disorders related to or resulting from use of or induced by substances or induced by intoxication from substances or abstinence from
- oestradiol would appear to increase dopamine release at striatum and nucleus accumbens level and contributes to the increase of cocaine vulnerability in female subjects.
- composition mainly in use is based upon opium.
- the dose of opium is gradually reduced to zero, in the various treatment steps, and administered to the patient.
- Replacement therapy is a short term.
- the treatment of choice is methadone which is used for the addicted patient, in particular heroin addicted.
- methadone can induce drug addiction, whereby 100 mg of methadone per os is equivalent to 10 mg of morphine administered i.v. .
- methadone itself may trigger various side effects such pulmonary lesions or oedema, immunological symptoms, impotence, and in more severe cases even blindness in both eyes.
- children born of methadone addicted mothers are also likely to be addicted. Therefore, the substitution therapy cannot be considered an ideal method in the treatment of addiction.
- steroid activity inhibitors in particular androgens, such as for example testosterone
- androgens such as for example testosterone
- the author of the present invention disclosed that the above mentioned active principles can be used advantageously for the treatment of compulsive obsessive disorders, depressive disorders, aggressive behaviours and recurrent criminal habit.
- the author of the present invention observed that the adolescence is one of the more hazardous periods for the beginning of substance abuse and drug addiction in young people. Numerous hypotheses have attempted to establish possible risk factors mainly based on the social , familiar distress and psychological problems. The author of the present invention observed that substance abuse and drug addiction can result from a sexual problem. This theory derives from a set of considerations: drug addiction occurs mostly during a period in which the puberty process is completed in young males, as it is known that in this life period changes in the personality and behaviour occur in parallel with testosterone production regulating the puberty; in epidemiological surveys young people interviewed answered in a significant percentage, that indeed a sexual disorder was one of the possible risk factors for substance abuse and late drug addiction (La Pera G. et.
- steroids in particular androgens, such as for example testosterone
- the above mentioned substances can be, for example, alcohol, amphetamines, caffeine, Cannabis, cocaine, hallucinogens, inhalants, nicotine, opiate, phencyclidine, sedatives, hypnotics, anxiolytics, drugs, psychoanalectics and drugs stimulating the central nervous system,, psycholeptics and drugs depressing the central nervous system or reducing the pain, psychodisleptics and drugs altering perceptive functions and perception, ecstasy, LSD, fungi (peyote).
- the aforesaid inhibitors can act on the non genomic effects of steroids or on genomic effects.
- the inhibition of genomic effects can occur through inhibition of the synthesis and steroid cytoplasmic receptor, inhibition of the formation of the complex between steroid receptor and ligand, by means of receptor antagonists, inhibition of the activity of the complex between steroid receptor and ligand.
- the inhibition of steroids activity can occur by means of inhibition of the genomic target the synthesis of which is regulated by the steroid-ligand complex.
- One particular group of compounds which can be used according to the present invention are the inhibitors of testosterone production and activity.
- the inhibition of testosterone production can occur by acting at hypophysis level using agonists of the LHRH synthesis or antagonists of the LHRH receptor, that is active principles able to operate directly on the feedback mechanism which is regulated mainly by the LHRH receptor at hypophysial level , or directly at gonadal level.
- Examples of compounds acting on the feedback mechanism at level of LHRH system are triptorelin, leuprorelin acetate, buserelin acetate, goserelin acetate.
- inhibitors of testosterone production by means of action on the gonads are, as an example, ketoconazol, aminoglutamide.
- the inhibitors of testosterone production are molecules able to markedly reduce the circulating levels of testosterone in order to obtain a chemical castration in male individuals until the same hormone levels are achieved, that can be obtained by of surgical castration (indicatively levels less than 1 ng/ml).
- the inhibitors of testosterone activity are for example oestrogens, antiandrogens, such as bicalutamide, cyproterone acetate, flutamide, danazol.
- the present invention concerns moreover the use of one or more inhibitors of the production, biosynthesis or its regulation, transport, metabolism or bioavailability of steroids as above described, in combination with other effective active principles for the treatment of addictions like, as an example, metadoxine, methadone hydrochloride, antidepressants.
- An inhibitor example of steroid transport is mepartricine.
- the inhibitors according to the present invention can be comprised in formulations such as, for example, tablets, capsules, solutions, suspensions, injectable compositions, suppositories, depot formulations, compositions for a controlled release of the active principle, as for example for one or three months.
- Inhibitors can be administered by any suitable mode, as for example, oral, intravenous, intramuscular, rectal, transdermal, transurethral, intraurethral, nasal route.
- ESEMPIO 2 Study on the cocaine addiction 25 year old, overweight, hirsutic female with polycystic ovary . In anamnesis the patient used cocaine several times over a week. The patient did not suffer from diabetes neither other important disease.
- the patient was treated with cyproterone acetate 50 mg 1 cp daily. In the course of the follow up transaminases and hormones were assayed. The treatment lasted approximately 9 months. After 6 months of therapy the girl was "drug free" and no longer used cocaine.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06728498A EP1879592A1 (en) | 2005-03-18 | 2006-03-17 | Use of inhibitors of steroid (testosterone) activity (i.a. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse |
CA002601051A CA2601051A1 (en) | 2005-03-18 | 2006-03-17 | Use of inhibitors of steroid (testosterone) activity (i. a. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse |
US11/886,523 US20080167282A1 (en) | 2005-03-18 | 2006-03-17 | Use of Inhibitors of Steroid Activity for the Treatment of Substance Related Disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2005A000127 | 2005-03-18 | ||
IT000127A ITRM20050127A1 (en) | 2005-03-18 | 2005-03-18 | USE OF INHIBITORS OF STEROID ACTIVITY FOR THE TREATMENT OF DISTURBANCES CORRELATED TO SUBSTANCES. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006097970A1 true WO2006097970A1 (en) | 2006-09-21 |
Family
ID=36678611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2006/000168 WO2006097970A1 (en) | 2005-03-18 | 2006-03-17 | Use of inhibitors of steroid (testosterone) activity (i. a. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080167282A1 (en) |
EP (1) | EP1879592A1 (en) |
CA (1) | CA2601051A1 (en) |
IT (1) | ITRM20050127A1 (en) |
WO (1) | WO2006097970A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20080436A1 (en) * | 2008-08-06 | 2010-02-07 | Francesco Marrosu | USE OF THE FINASTERIDE AND OTHER INHIBITING SUBSTANCES OF THE ENZYME 5-A-REDUTTASI FOR THE PREVENTION AND CARE OF THE IMPULSE AND AGGRESSIVE DISTURBANCES |
RU2694262C1 (en) * | 2018-05-11 | 2019-07-11 | Бюджетное учреждение высшего образования Ханты-Мансийского автономного округа-Югры "Ханты-Мансийская государственная медицинская академия" | Method of treating compensated and decompensated disturbed cardiac hemodynamic in acute verapamil poisoning |
-
2005
- 2005-03-18 IT IT000127A patent/ITRM20050127A1/en unknown
-
2006
- 2006-03-17 CA CA002601051A patent/CA2601051A1/en not_active Abandoned
- 2006-03-17 US US11/886,523 patent/US20080167282A1/en not_active Abandoned
- 2006-03-17 EP EP06728498A patent/EP1879592A1/en not_active Withdrawn
- 2006-03-17 WO PCT/IT2006/000168 patent/WO2006097970A1/en not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1981, LAKOZA G N ET AL: "SIGNIFICANCE OF THE ADRENOLYTIC PROPERTIES OF NEUROLEPTICS IN THEIR EFFECT ON ETHANOL ADDICTION", XP002391944, Database accession no. PREV198376037216 * |
FARMAKOLOGIYA I TOKSIKOLOGIYA (MOSCOW), vol. 44, no. 2, 1981, pages 151 - 154, ISSN: 0014-8318 * |
G.N. LAKOZA, N.K. BARKOV: "The role of testosterone in the development of experimental alcoholism", UNITED NATIONS BULLETIN ON NARCOTICS, no. 2, 1980, pages 41 - 48, XP002392127, Retrieved from the Internet <URL:http://www.unodc.org/unodc/bulletin/bulletin_1980-01-01_2_page007.html#s070> [retrieved on 20060726] * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20080436A1 (en) * | 2008-08-06 | 2010-02-07 | Francesco Marrosu | USE OF THE FINASTERIDE AND OTHER INHIBITING SUBSTANCES OF THE ENZYME 5-A-REDUTTASI FOR THE PREVENTION AND CARE OF THE IMPULSE AND AGGRESSIVE DISTURBANCES |
RU2694262C1 (en) * | 2018-05-11 | 2019-07-11 | Бюджетное учреждение высшего образования Ханты-Мансийского автономного округа-Югры "Ханты-Мансийская государственная медицинская академия" | Method of treating compensated and decompensated disturbed cardiac hemodynamic in acute verapamil poisoning |
Also Published As
Publication number | Publication date |
---|---|
CA2601051A1 (en) | 2006-09-21 |
ITRM20050127A1 (en) | 2006-09-19 |
EP1879592A1 (en) | 2008-01-23 |
US20080167282A1 (en) | 2008-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pandya et al. | Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study | |
Carlsson et al. | A regional study of sex differences in rat brain serotonin | |
Berendsen | The role of serotonin in hot flushes | |
Arborelius et al. | 5-HT 1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram | |
Newman et al. | Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review | |
Reddy | Neurosteroids and their role in sex-specific epilepsies | |
Taylor et al. | Changing concepts of the biochemical action of the anxioselective drug, buspirone | |
Mecawi et al. | Estradiol potentiates hypothalamic vasopressin and oxytocin neuron activation and hormonal secretion induced by hypovolemic shock | |
Peltier et al. | Role of exogenous progesterone in the treatment of men and women with substance use disorders: a narrative review | |
Tottori et al. | Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523 | |
Eriksson et al. | Diagnosis and treatment of premenstrual dysphoria | |
Al-Quliti et al. | New advances in prevention of migraine: Review of current practice and recent advances | |
Hellstrom et al. | Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment | |
Desai et al. | Understanding and treating ejaculatory dysfunction in men with diabetes mellitus | |
US20080167282A1 (en) | Use of Inhibitors of Steroid Activity for the Treatment of Substance Related Disorders | |
Reddy et al. | Does stress trigger seizures? Evidence from experimental models | |
CN101495121A (en) | Methods for the treatment of substance abuse and dependence | |
NZ537643A (en) | Treatment of urinary dysfunction by regulating expression P2X receptors using phytoestrogen isoflavones progestins or estrogens | |
Toot et al. | Testosterone influences renal electrolyte excretion in SHR/y and WKY males | |
Webb et al. | Estrogen reduces the severity of autonomic dysfunction in spinal cord-injured male mice | |
Love et al. | Tamoxifen therapy in breast cancer control worldwide. | |
Lintzeris et al. | Addressing dependent amphetamine use: a place for prescription | |
JP2004529142A (en) | Intermittent reductions in the levels of cortisol and other adrenal hormones in humans and animals as a treatment for clinical conditions associated with abnormal levels of these hormones | |
Malandain et al. | Psychopharmacotherapy of Sexual Disorders | |
Mohammed et al. | Drug Information of Lasmiditan and Its Effectiveness for Maigraine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2601051 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11886523 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006728498 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006728498 Country of ref document: EP |